Alkermes PLC (ALKS) to Release Quarterly Earnings on Thursday
Alkermes PLC (NASDAQ:ALKS) will post its quarterly earnings results before the market opens on Thursday, October 26th. Analysts expect Alkermes PLC to post earnings of $0.01 per share for the quarter.
Alkermes PLC (NASDAQ:ALKS) last posted its quarterly earnings data on Thursday, July 27th. The company reported $0.01 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.02. Alkermes PLC had a negative return on equity of 9.12% and a negative net margin of 24.33%. The company had revenue of $218.80 million during the quarter, compared to analyst estimates of $216.54 million. During the same quarter last year, the company earned ($0.01) EPS. The firm’s revenue for the quarter was up 12.1% on a year-over-year basis. On average, analysts expect Alkermes PLC to post $-0.68 EPS for the current fiscal year and $-0.39 EPS for the next fiscal year.
Alkermes PLC (NASDAQ:ALKS) traded down 0.22% on Friday, reaching $50.45. The company had a trading volume of 25,420 shares. The stock’s 50-day moving average is $51.19 and its 200-day moving average is $55.33. The company’s market capitalization is $7.75 billion. Alkermes PLC has a 52 week low of $48.90 and a 52 week high of $63.40.
In other Alkermes PLC news, CAO Kathryn L. Biberstein sold 13,566 shares of the stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $51.29, for a total value of $695,800.14. Following the completion of the sale, the chief accounting officer now owns 70,455 shares in the company, valued at approximately $3,613,636.95. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Paul J. Mitchell sold 1,500 shares of the stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $54.91, for a total transaction of $82,365.00. Following the completion of the sale, the director now owns 9,500 shares of the company’s stock, valued at approximately $521,645. The disclosure for this sale can be found here. Insiders sold a total of 18,066 shares of company stock worth $930,280 over the last ninety days. 5.34% of the stock is currently owned by corporate insiders.
ALKS has been the topic of a number of recent analyst reports. ValuEngine downgraded Alkermes PLC from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. Zacks Investment Research raised Alkermes PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, August 2nd. BidaskClub downgraded Alkermes PLC from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Jefferies Group LLC set a $69.00 target price on Alkermes PLC and gave the company a “buy” rating in a research report on Friday, August 25th. Finally, Barclays PLC downgraded Alkermes PLC from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $66.00 to $50.00 in a research report on Monday. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. Alkermes PLC has an average rating of “Hold” and a consensus price target of $62.56.
Alkermes PLC Company Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.